Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Halofuginone: a novel antifibrotic therapy

M Pines1, A Nagler

  • 1Institute of Animal Science, Volcani Center, Bet Dagan, Israel.

General Pharmacology
|April 2, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-myeloablative versus reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients aged ≥65: a study from the ALWP of EBMT.

Bone marrow transplantation·2026
Same author

Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA).

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Metabolic syndrome and cardiovascular disease after haematopoietic cell transplantation (HCT) in adults: an EBMT cross-sectional non-interventional study.

Bone marrow transplantation·2021
Same author

Impact of patient: donor HLA disparity on reduced-intensity-conditioned allogeneic stem cell transplants from HLA mismatched unrelated donors for AML: from the ALWP of the EBMT.

Bone marrow transplantation·2020
Same author

Nilotinib in steroid-refractory cGVHD: prospective parallel evaluation of response, according to NIH criteria and exploratory response criteria (GITMO criteria).

Bone marrow transplantation·2020
Same author

Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2019

Halofuginone effectively inhibits collagen type I gene expression and synthesis, demonstrating potential as an anti-fibrotic therapy. This compound targets key mechanisms in fibrosis, offering a promising treatment for excessive connective tissue accumulation.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Pharmacology

Background:

  • Fibrosis involves excessive extracellular matrix deposition, primarily collagen type I, disrupting tissue architecture and function.
  • Fibrosis is a common pathological response to diverse injuries and cellular dysfunctions across various tissues.

Purpose of the Study:

  • To evaluate the anti-fibrotic potential of halofuginone.
  • To investigate halofuginone's effect on collagen type I gene expression and synthesis.

Main Methods:

  • Assessed halofuginone's impact on collagen alpha 1(I) gene expression and collagen synthesis in human fibroblast cell cultures.
  • Evaluated halofuginone's efficacy in animal models of induced fibrosis across multiple tissues (skin, liver, lung).
  • Administered halofuginone via intraperitoneal injection, dietary addition, or local application in animal models.

Related Experiment Videos

Main Results:

  • Halofuginone significantly inhibited collagen alpha 1(I) gene expression and collagen synthesis in vitro.
  • Halofuginone demonstrated efficacy in reducing collagen deposition in various fibrotic animal models.
  • A clinical case showed halofuginone decreased skin collagen in a patient with chronic graft-versus-host disease.

Conclusions:

  • Halofuginone exhibits specific and transient inhibition of collagen alpha 1(I) synthesis at the transcriptional level.
  • The findings suggest halofuginone is a promising candidate for effective anti-fibrotic therapy.
  • Halofuginone's targeted mechanism and demonstrated efficacy support its therapeutic potential in fibrotic diseases.